Curat Global LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Curat Global LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, Holdings Channel.com reports. The firm acquired 50 shares of the biopharmaceutical company’s stock, valued at approximately $32,000.

A number of other large investors also recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the period. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Finally, Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 2.1%

REGN opened at $493.22 on Friday. The stock has a market capitalization of $53.25 billion, a P/E ratio of 12.88, a P/E/G ratio of 2.34 and a beta of 0.31. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm’s fifty day simple moving average is $569.75 and its 200 day simple moving average is $657.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the firm earned $9.55 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Analysts Set New Price Targets

REGN has been the topic of several recent research reports. Robert W. Baird reduced their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research report on Friday, April 25th. UBS Group reduced their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a report on Thursday. Citigroup decreased their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, June 2nd. Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $700.00 to $580.00 in a research note on Friday, May 30th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $844.48.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.